Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
SOLO2 ancillary study findings will help assure patients that their outcomes will not be adversely affected when dose reductions or interruptions are needed
New indications concern the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma and the adjuvant treatment of muscle invasive urothelial carcinoma
Most patients were on active anticancer treatment during the 28 days before the administration of third dose
Findings from the international metastatic renal cell database consortium
Stimufend is a biosimilar, highly similar to the reference product Neulasta (pegfilgrastim), which was authorised in the EU in 2002
Improvements also observed with respect to key secondary endpoints, with no increase in adverse events
EMA starts safety review of Janus kinase inhibitors used for inflammatory disorders
Additional declines in cancer mortality rates predicted for 2022
The study primary endpoint is event-free survival, and lack of improvement in pathologic complete response may be misleading as to the impact of atezolizumab on long-term efficacy in high-risk triple-negative breast cancer
Findings from the Danish Breast Cancer Group
Final results from the FIGHT-101 study
Findings from the COVID-19 and Cancer Consortium cohort study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
